<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prevention of Candida infection in neonates</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prevention of Candida infection in neonates</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prevention of Candida infection in neonates</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mohan Pammi, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen M Puopolo, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Candida</em> is a major cause of neonatal infection in preterm infants, especially in extremely low and very low birth weight infants [<a href="#rid1">1-4</a>]. Successful management of neonatal candidiasis requires effective treatment of <em>Candida</em> infection with appropriate antifungal therapy, supportive care, and preventive measures to reduce the risk of systemic <em>Candida</em> infections.</p><p>The prevention of <em>Candida</em> infections in preterm neonates will be reviewed here. The clinical manifestations, diagnosis, etiology, risk factors, and treatment of neonatal candidal infections are discussed separately. (See  <a class="medical medical_review" href="/d/html/5024.html" rel="external">"Clinical manifestations and diagnosis of Candida infection in neonates"</a> and  <a class="medical medical_review" href="/d/html/5028.html" rel="external">"Epidemiology and risk factors for Candida infection in neonates"</a> and  <a class="medical medical_review" href="/d/html/5029.html" rel="external">"Treatment of Candida infection in neonates"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">BACKGROUND</span><span class="headingEndMark"> — </span>Prevention of systemic candidal infections in preterm neonates is important because candidemia is associated with poor clinical outcomes in this population. Prevention efforts have focused on the very low birth weight (birth weight &lt;1500 g) and extremely low birth weight (ELBW; birth weight &lt;1000 g) infants who are at the highest risk for invasive candidal infections. (See  <a class="medical medical_review" href="/d/html/5028.html" rel="external">"Epidemiology and risk factors for Candida infection in neonates", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/d/html/5028.html" rel="external">"Epidemiology and risk factors for Candida infection in neonates", section on 'Risk factors for invasive candidiasis'</a>.)</p><p>Preventive management includes general measures that can be applied broadly to all infants in the neonatal intensive care unit (NICU) and administration of prophylactic antifungal agents, which is reserved for ELBW infants who are cared for in NICUs with a high baseline rate of systemic fungal infection.</p><p class="headingAnchor" id="H3"><span class="h1">GENERAL MEASURES</span><span class="headingEndMark"> — </span>General measures are focused upon reducing cross-infection of <em>Candida</em> in the neonatal intensive care unit (NICU) and risk factors that increase the likelihood of candidemia. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Handwashing, use of gloves, and avoidance of artificial fingernails to reduce the rate of horizontal transmission from health care worker to infant – However, these measures alone may not be sufficient to prevent horizontal transmission, because of the difficulty in eradicating <em>Candida</em> from the hands of health care workers. In one study, commonly used antiseptics or disinfectants for handwashing demonstrated varying degrees of in vitro inhibition of growth of <em>Candida</em> species recovered from hospitalized patients [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Single-room isolation or cohorting infants who are known to be colonized or infected with <em>Candida</em> – With this intervention, health care workers can be segregated to only caring for infants with candidal colonization/infection and caring for noninfected/noncolonized infants. Although patient isolation or cohorting is often a recommended routine infection control measure, there are no clinical trials demonstrating that this practice prevents <em>Candida</em> cross-infection in the NICU [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduction of risk factors associated with <em>Candida</em> overgrowth (ie, high density of candidal colonization), which increases the likelihood of disseminated systemic infection – Interventions that promote overgrowth of <em>Candida</em> include H2 receptor antagonists, proton pump inhibitors, broad-spectrum antibiotics (eg, third-generation cephalosporins and imipenems), and glucocorticoids [<a href="#rid7">7-9</a>]. In addition, the use of topical petrolatum is associated with an increase in invasive fungal infection [<a href="#rid10">10</a>]. Minimizing or avoiding these risk factors, if clinically appropriate, may decrease the density of candidal colonization and the likelihood of candidemia [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/5028.html" rel="external">"Epidemiology and risk factors for Candida infection in neonates", section on 'Risk factors for invasive candidiasis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medical hardware, such as central venous catheters, that provides a site for bloodstream invasion and/or colonization – Removing central venous catheters once they are no longer needed helps to reduce all types of nosocomial bacteremia, including candidemia. Nutrition policies that promote early initiation and advancement of enteral feeding may reduce central line days. (See  <a class="medical medical_review" href="/d/html/5026.html" rel="external">"Parenteral nutrition in premature infants"</a> and  <a class="medical medical_review" href="/d/html/5014.html" rel="external">"Approach to enteral nutrition in the premature infant"</a>.).</p><p></p><p class="headingAnchor" id="H4"><span class="h1">ANTIFUNGAL PROPHYLAXIS</span></p><p class="headingAnchor" id="H1548645849"><span class="h2">Targeted prophylaxis</span><span class="headingEndMark"> — </span>Based upon the available evidence, our approach is to use a targeted approach to antifungal prophylaxis rather than routinely providing prophylaxis for all preterm infants. This approach is consistent with the recommendations of the American Academy of Pediatrics and the Infectious Diseases Society of America [<a href="#rid12">12-14</a>]. Broad use of antifungal prophylaxis for all preterm infants is discouraged because of the concern of promoting resistant <em>Candida</em> species within the NICU. Universal prophylaxis in an NICU with a low incidence of candidiasis would expose a large number of infants to <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a> to prevent a single case of infection.</p><p>Targeted antifungal prophylaxis is reserved for extremely low birth weight (ELBW) infants who are at high risk of <em>Candida</em> infection, including:</p><p class="bulletIndent1"><span class="glyph">●</span>ELBW infants cared for in neonatal intensive care units (NICUs) with a high baseline rate of systemic fungal infection (ie, greater than 5 to 10 percent), or</p><p class="bulletIndent1"><span class="glyph">●</span>ELBW infants who require antibiotic therapy for &gt;48 hours (eg, for a confirmed bacterial infection or necrotizing enterocolitis)</p><p></p><p class="headingAnchor" id="H1318840720"><span class="h2">Choice of agent</span><span class="headingEndMark"> — </span>When antifungal prophylaxis is provided, we suggest <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a> rather than other agents. (See <a class="local">'Fluconazole'</a> below.)</p><p>We prefer <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a> over other agents because it is the drug that has been studied most commonly in high-quality clinical trials and it has demonstrated efficacy in this setting [<a href="#rid15">15</a>]. Oral <a class="drug drug_pediatric" data-topicid="12654" href="/d/drug information/12654.html" rel="external">nystatin</a> is a reasonable alternative. Studies directly comparing fluconazole with nystatin are limited to three small trials with very few events. In a meta-analysis of the three trials, the overall rate of invasive fungal infection was lower with fluconazole compared with nystatin; however, the findings was not statistically significant (3 versus 6 percent; risk ratio 0.53, 95% CI 0.19-1.52) [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Fluconazole</span><span class="headingEndMark"> — </span>Clinical trials in preterm infants have demonstrated that prophylactic <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a> reduces candidal colonization and invasive infection in preterm infants [<a href="#rid15">15-17</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">Fluconazole</a> is started within the first 48 to 72 hours after birth at a dose of 6 mg/kg per dose given intravenously (IV) or enterally twice a week for four to six weeks or until the infant no longer requires IV access [<a href="#rid12">12,18,19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy in reducing invasive fungal infection</strong> – In a meta-analysis of 10 trials (including 1371 very preterm or VLBW infants), systemic antifungal prophylaxis reduced the incidence of invasive fungal infection compared with placebo or no drug (6.2 versus 15.7 percent; RR 0.43, 95% CI 0.31-0.59); the effect on mortality was not statistically significant (12.7 versus 17.3 percent; RR 0.79, 95% CI 0.61-1.02) [<a href="#rid15">15</a>]. Nine of the 10 trials used systemic <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a> prophylaxis. Results were similar among ELBW (ie, birth weight &lt;1000 g) infants who are the most vulnerable to invasive candidiasis. In the subgroup analysis (which included two studies with a total of 461 ELBW infants), systemic antifungal prophylaxis reduced the incidence of invasive fungal infection (RR 0.30, 95% CI 0.14-0.63), but the effect on mortality was not statistically significant (RR 0.82, 95% CI 0.55-1.23). The trials in the meta-analysis were generally of good methodologic quality; however, the incidence of baseline invasive candidal infection in these trials (16 percent) was much higher than that reported from large cohort studies (&lt;5 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term effects</strong> – Data on long-term outcomes for neonates treated with prophylactic <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a> are very limited. In the few patients evaluated, there appears to be no long-term adverse effects of prophylactic fluconazole therapy in ELBW survivors [<a href="#rid20">20</a>]. In the previously discussed meta-analysis, one trial found no difference in neurodevelopmental status and quality of life in the 38 of the 86 survivors who were evaluated in a follow-up study [<a href="#rid20">20-22</a>]. There were also no differences in growth or long-term risk of cholestasis. In a clinical trial of ELBW infants, after adjusting for confounding factors, there was no difference in neurodevelopmental outcomes at 18 to 22 months corrected age between the fluconazole prophylaxis and control groups, based on Bayley-III cognition composite scores, or a diagnosis of blindness, deafness, or cerebral palsy [<a href="#rid16">16</a>].</p><p></p><p class="headingAnchor" id="H3482336318"><span class="h3">Nystatin and miconazole</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12654" href="/d/drug information/12654.html" rel="external">Nystatin</a> and <a class="drug drug_pediatric" data-topicid="16825" href="/d/drug information/16825.html" rel="external">miconazole</a> are local antifungal agents without systemic distribution because they are not well absorbed from the gastrointestinal tract.</p><p>Several trials have shown that prophylactic use of oral or topical nonabsorbed agents reduces the risk of candidiasis [<a href="#rid23">23-27</a>]. In a meta-analysis of four trials (including 1800 very preterm or very low birth weight [VLBW] infants), prophylactic therapy reduced the incidence of invasive fungal infection compared with placebo (relative risk [RR] 0.2, 95% CI 0.14-0.27); the effect on mortality was nonsignificant (RR 0.87, 95% CI 0.72-1.05) [<a href="#rid21">21</a>]. However, these results need to be interpreted cautiously because of methodologic limitations of the included trials (including quasi-randomization, lack of allocation concealment, and lack of blinding of intervention and outcomes assessment) and because there was significant heterogeneity between trials.</p><p class="headingAnchor" id="H8"><span class="h2">No role for surveillance cultures</span><span class="headingEndMark"> — </span>Systematic screening for <em>Candida</em> colonization has been suggested as a possible tool in preventing fungal infections in high-risk patients by initiating antifungal therapy when colonization is detected [<a href="#rid28">28</a>]. However, this approach is not routinely used in most NICUs. Further studies are needed to determine if the benefits outweigh the risks and costs of screening for fungal colonization in high-risk neonates and if antifungal therapy should be initiated when colonization is detected.</p><p class="headingAnchor" id="H207853895"><span class="h1">EMPIRIC ANTIFUNGAL THERAPY</span><span class="headingEndMark"> — </span>There are no guidelines for initiating empiric therapy for invasive candidiasis like those that exist for group B <em>Streptococcus</em> infections. While early empiric antifungal therapy (ie, prior to receiving culture results) theoretically might improve outcomes for neonates with candidemia, it is generally not part of routine NICU practice since <em>Candida </em>accounts for a only small proportion of all late-onset bloodstream infections in this population. (See  <a class="medical medical_review" href="/d/html/5028.html" rel="external">"Epidemiology and risk factors for Candida infection in neonates", section on 'Epidemiology'</a>.)</p><p>In an observational study of 136 extremely low birth weight (ELBW) infants with invasive candidiasis who were cared for at the National Institute of Child Health and Human Development's Neonatal Research Network sites in the United States, mortality rates were similar for infants who did or did not receive empiric antifungal therapy prior to culture results (33 versus 35 percent, respectively) [<a href="#rid29">29</a>]. However, those who received empiric antifungal therapy were more likely to survive without neurodevelopmental impairment (50 versus 36 percent). </p><p>The approach to managing suspected invasive candidiasis in neonates is presented separately. (See  <a class="medical medical_review" href="/d/html/5029.html" rel="external">"Treatment of Candida infection in neonates", section on 'Invasive infection'</a>.)</p><p class="headingAnchor" id="H454916249"><span class="h1">LACTOFERRIN AND PROBIOTICS</span><span class="headingEndMark"> — </span>The use of lactoferrin and/or probiotics to reduce gastrointestinal <em>Candida</em> colonization has been suggested. However, until it has been shown that this intervention is beneficial and safe, and an effective standardized regimen has been developed, the use of lactoferrin and probiotics should be limited to clinical trials.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lactoferrin</strong> – Based on the available evidence, it remains uncertain if lactoferrin supplementation meaningfully reduces fungal sepsis in preterm infants. If there is an effect, it appears to be small. In a 2020 meta-analysis of six trials (3266 infants), enteral lactoferrin supplementation decreased invasive fungal infection compared with placebo (0.4 versus 1.7 percent; relative risk [RR] 0.23, 95% CI 0.10-0.54) [<a href="#rid30">30</a>]. However, there were few events (33 total episodes in the six trials), the absolute effect size was small (absolute risk difference 1.3 percent [98% CI 0.8-1.5]), and two of the trials had important methodologic limitations that may have biased the findings. In the largest trial, which involved &gt;2200 preterm neonates randomized to enteral bovine lactoferrin or placebo (sucrose), rates of documented fungal sepsis were similar in both groups (0.3 versus 0.2 percent, respectively) [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Probiotics</strong> – The use of probiotics to prevent fungal and bacterial infections in neonates has been studied in randomized clinical trials [<a href="#rid32">32</a>]. However, important uncertainties and safety concerns remain, and we suggest <strong>not</strong> routinely using probiotics for this purpose. </p><p></p><p class="bulletIndent1">In a meta-analysis of two trials (329 patients), probiotics reduced rates <em>of Candida</em> colonization in preterm infants (12 versus 31 percent; RR 0.43, 95% CI 0.27-0.68) [<a href="#rid32">32</a>]. Despite the apparent large effect in reducing colonization, probiotics did not appear to have a meaningful impact on reducing the incidence of fungal sepsis (1.8 versus 2 percent; RR 0.88, 95% CI 0.44-1.78; six trials, 1259 patients). The studies included in the meta-analysis varied considerably with regard to the probiotic product used and birth weight and gestational age of enrolled infants. In addition, the individual trials were relatively small (80 to 400 patients) and many were deemed to be at high risk of bias.</p><p></p><p class="bulletIndent1">Other important uncertainties remain, including optimal probiotic strains, doses, and duration of therapy. Appropriate regulatory control of these products is another unresolved issue. In addition, rare but serious cases of probiotic-associated sepsis have been reported [<a href="#rid33">33-36</a>]. </p><p></p><p>Lactoferrin and probiotics for the prevention of sepsis in preterm neonates are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/89456.html" rel="external">"Treatment and prevention of bacterial sepsis in preterm infants &lt;34 weeks gestation", section on 'Potential prophylactic therapy'</a>.)</p><p class="headingAnchor" id="H1035465982"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/104270.html" rel="external">"Society guideline links: Candidiasis"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance </strong>– Prevention of systemic candidal infections in preterm neonates is important because candidemia is associated with poor clinical outcomes in this population. Prevention efforts have focused on the very low birth weight (birth weight &lt;1500 g) and extremely low birth weight (ELBW; birth weight &lt;1000 g) infants who are at the highest risk for invasive candidal infections. (See  <a class="medical medical_review" href="/d/html/5024.html" rel="external">"Clinical manifestations and diagnosis of Candida infection in neonates"</a> and  <a class="medical medical_review" href="/d/html/5028.html" rel="external">"Epidemiology and risk factors for Candida infection in neonates"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Our suggested approach</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General measures</strong> – General preventive measures to reduce neonatal candidal infection include efforts aimed at reducing candidal cross-infection (eg, handwashing and use of gloves) and efforts aimed at reducing the risk factors for candidemia (eg, antibiotic stewardship limiting use of broad-spectrum antibiotics, removing central venous catheters once they are no longer needed). (See <a class="local">'General measures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Selective use of antifungal prophylaxis in high-risk neonates</strong> – For ELBW infants who are at increased risk of candidal infection (eg, those cared for in centers where the rate of fungal infections is &gt;5 percent or those who require antibiotic therapy for &gt;48 hours), we suggest prophylactic antifungal therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). For other preterm neonatal populations, routine use of fungal prophylaxis is generally <strong>not</strong> necessary. Broad use of antifungal prophylaxis for all preterm infants is discouraged because of the concern of promoting resistant <em>Candida</em> species within the neonatal intensive care unit (NICU). Universal prophylaxis in an NICU with a low incidence of candidiasis would expose a large number of infants to antifungal therapy to prevent a single infection. (See <a class="local">'Antifungal prophylaxis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preferred prophylactic antifungal agent</strong> – When prophylactic antifungal therapy is used, we suggest <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a> rather than other agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Fluconazole is started within the first 48 to 72 hours after birth at dose of 6 mg/kg per dose given intravenously (IV) or enterally twice a week for four to six weeks or until the infant no longer requires IV access. We prefer fluconazole over other agents because it is the drug that has been most commonly studied in high-quality clinical trials and it has demonstrated efficacy in this setting. (See <a class="local">'Fluconazole'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Strategies not recommended</strong> - We suggest <strong>not</strong> using lactoferrin supplementation or probiotics for the purpose of reducing fungal infections in preterm neonates (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Lactoferrin and probiotics'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J 1998; 17:504.</a></li><li><a class="nounderline abstract_t">Beck-Sague CM, Azimi P, Fonseca SN, et al. Bloodstream infections in neonatal intensive care unit patients: results of a multicenter study. Pediatr Infect Dis J 1994; 13:1110.</a></li><li><a class="nounderline abstract_t">Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002; 110:285.</a></li><li><a class="nounderline abstract_t">Fridkin SK, Kaufman D, Edwards JR, et al. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics 2006; 117:1680.</a></li><li><a class="nounderline abstract_t">Silverman J, Vazquez JA, Sobel JD, Zervos MJ. Comparative in vitro activity of antiseptics and disinfectants versus clinical isolates of Candida species. Infect Control Hosp Epidemiol 1999; 20:676.</a></li><li><a class="nounderline abstract_t">Mohan P, Eddama O, Weisman LE. Patient isolation measures for infants with candida colonization or infection for preventing or reducing transmission of candida in neonatal units. Cochrane Database Syst Rev 2007; :CD006068.</a></li><li><a class="nounderline abstract_t">Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000; 19:319.</a></li><li><a class="nounderline abstract_t">Saiman L, Ludington E, Dawson JD, et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001; 20:1119.</a></li><li><a class="nounderline abstract_t">Kaufman DA. Challenging issues in neonatal candidiasis. Curr Med Res Opin 2010; 26:1769.</a></li><li><a class="nounderline abstract_t">Campbell JR, Zaccaria E, Baker CJ. Systemic candidiasis in extremely low birth weight infants receiving topical petrolatum ointment for skin care: a case-control study. Pediatrics 2000; 105:1041.</a></li><li><a class="nounderline abstract_t">Kaufman D. Strategies for prevention of neonatal invasive candidiasis. Semin Perinatol 2003; 27:414.</a></li><li class="breakAll">American Academy of Pediatrics. Candidiasis. In: Red Book: 2021–2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, 2021. p.246.</li><li><a class="nounderline abstract_t">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a class="nounderline abstract_t">Healy CM, Baker CJ. Fluconazole prophylaxis in the neonatal intensive care unit. Pediatr Infect Dis J 2009; 28:49.</a></li><li><a class="nounderline abstract_t">Cleminson J, Austin N, McGuire W. Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev 2015; :CD003850.</a></li><li><a class="nounderline abstract_t">Benjamin DK Jr, Hudak ML, Duara S, et al. Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial. JAMA 2014; 311:1742.</a></li><li><a class="nounderline abstract_t">Robati Anaraki M, Nouri-Vaskeh M, Abdoli Oskoei S. Fluconazole prophylaxis against invasive candidiasis in very low and extremely low birth weight preterm neonates: a systematic review and meta-analysis. Clin Exp Pediatr 2021; 64:172.</a></li><li><a class="nounderline abstract_t">Leonart LP, Tonin FS, Ferreira VL, et al. Fluconazole Doses Used for Prophylaxis of Invasive Fungal Infection in Neonatal Intensive Care Units: A Network Meta-Analysis. J Pediatr 2017.</a></li><li><a class="nounderline abstract_t">Wade KC, Benjamin DK Jr, Kaufman DA, et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J 2009; 28:717.</a></li><li><a class="nounderline abstract_t">Kaufman DA, Cuff AL, Wamstad JB, et al. Fluconazole prophylaxis in extremely low birth weight infants and neurodevelopmental outcomes and quality of life at 8 to 10 years of age. J Pediatr 2011; 158:759.</a></li><li><a class="nounderline abstract_t">Austin N, Cleminson J, Darlow BA, McGuire W. Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants. Cochrane Database Syst Rev 2015; :CD003478.</a></li><li><a class="nounderline abstract_t">Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001; 345:1660.</a></li><li><a class="nounderline abstract_t">Austin N, Darlow BA, McGuire W. Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants. Cochrane Database Syst Rev 2013; :CD003478.</a></li><li><a class="nounderline abstract_t">Sims ME, Yoo Y, You H, et al. Prophylactic oral nystatin and fungal infections in very-low-birthweight infants. Am J Perinatol 1988; 5:33.</a></li><li><a class="nounderline abstract_t">Ozturk MA, Gunes T, Koklu E, et al. Oral nystatin prophylaxis to prevent invasive candidiasis in Neonatal Intensive Care Unit. Mycoses 2006; 49:484.</a></li><li><a class="nounderline abstract_t">Wainer S, Cooper PA, Funk E, et al. Prophylactic miconazole oral gel for the prevention of neonatal fungal rectal colonization and systemic infection. Pediatr Infect Dis J 1992; 11:713.</a></li><li><a class="nounderline abstract_t">Mersal A, Alzahrani I, Azzouz M, et al. Oral Nystatin Versus Intravenous Fluconazole as Neonatal Antifungal Prophylaxis: Non-inferiority Trial. J Clin Neonatol 2013; 2:88.</a></li><li><a class="nounderline abstract_t">Vendettuoli V, Tana M, Tirone C, et al. The role of Candida surveillance cultures for identification of a preterm subpopulation at highest risk for invasive fungal infection. Pediatr Infect Dis J 2008; 27:1114.</a></li><li><a class="nounderline abstract_t">Greenberg RG, Benjamin DK Jr, Gantz MG, et al. Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis. J Pediatr 2012; 161:264.</a></li><li><a class="nounderline abstract_t">Pammi M, Suresh G. Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2020; 3:CD007137.</a></li><li><a class="nounderline abstract_t">ELFIN trial investigators group. Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial. Lancet 2019; 393:423.</a></li><li><a class="nounderline abstract_t">Hu HJ, Zhang GQ, Zhang Q, et al. Probiotics Prevent Candida Colonization and Invasive Fungal Sepsis in Preterm Neonates: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pediatr Neonatol 2017; 58:103.</a></li><li><a class="nounderline abstract_t">Esaiassen E, Cavanagh P, Hjerde E, et al. Bifidobacterium longum Subspecies infantis Bacteremia in 3 Extremely Preterm Infants Receiving Probiotics. Emerg Infect Dis 2016; 22:1664.</a></li><li><a class="nounderline abstract_t">Bertelli C, Pillonel T, Torregrossa A, et al. Bifidobacterium longum bacteremia in preterm infants receiving probiotics. Clin Infect Dis 2015; 60:924.</a></li><li><a class="nounderline abstract_t">Zbinden A, Zbinden R, Berger C, Arlettaz R. Case series of Bifidobacterium longum bacteremia in three preterm infants on probiotic therapy. Neonatology 2015; 107:56.</a></li><li><a class="nounderline abstract_t">Jenke A, Ruf EM, Hoppe T, et al. Bifidobacterium septicaemia in an extremely low-birthweight infant under probiotic therapy. Arch Dis Child Fetal Neonatal Ed 2012; 97:F217.</a></li></ol></div><div id="topicVersionRevision">Topic 5042 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9655543" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7892080" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Bloodstream infections in neonatal intensive care unit patients: results of a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12165580" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16651324" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10530645" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparative in vitro activity of antiseptics and disinfectants versus clinical isolates of Candida species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17636825" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Patient isolation measures for infants with candida colonization or infection for preventing or reducing transmission of candida in neonatal units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10783022" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11740316" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk factors for Candida species colonization of neonatal intensive care unit patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20513206" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Challenging issues in neonatal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10790460" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Systemic candidiasis in extremely low birth weight infants receiving topical petrolatum ointment for skin care: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14626506" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Strategies for prevention of neonatal invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14626506" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Strategies for prevention of neonatal invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19106754" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Fluconazole prophylaxis in the neonatal intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26497056" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24794367" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32683818" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Fluconazole prophylaxis against invasive candidiasis in very low and extremely low birth weight preterm neonates: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28285752" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Fluconazole Doses Used for Prophylaxis of Invasive Fungal Infection in Neonatal Intensive Care Units: A Network Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19593252" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21168853" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Fluconazole prophylaxis in extremely low birth weight infants and neurodevelopmental outcomes and quality of life at 8 to 10 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26497202" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11759644" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Fluconazole prophylaxis against fungal colonization and infection in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23543519" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3276336" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prophylactic oral nystatin and fungal infections in very-low-birthweight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17022766" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Oral nystatin prophylaxis to prevent invasive candidiasis in Neonatal Intensive Care Unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1448310" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prophylactic miconazole oral gel for the prevention of neonatal fungal rectal colonization and systemic infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24049751" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Oral Nystatin Versus Intravenous Fluconazole as Neonatal Antifungal Prophylaxis: Non-inferiority Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18978516" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The role of Candida surveillance cultures for identification of a preterm subpopulation at highest risk for invasive fungal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22424952" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32232984" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30635141" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27793494" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Probiotics Prevent Candida Colonization and Invasive Fungal Sepsis in Preterm Neonates: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27532215" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Bifidobacterium longum Subspecies infantis Bacteremia in 3 Extremely Preterm Infants Receiving Probiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25472946" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Bifidobacterium longum bacteremia in preterm infants receiving probiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25402825" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Case series of Bifidobacterium longum bacteremia in three preterm infants on probiotic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22058179" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Bifidobacterium septicaemia in an extremely low-birthweight infant under probiotic therapy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
